The AVENIO Tumor Tissue Targeted Kit V2 is a next-generation sequencing (NGS) research assay for genomic profiling of solid tumors from formalin-fixed paraffin-embedded (FFPE) tissue samples. It contains 17 guideline-aligned biomarkers, including those in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines.2
Features and Benefits
- Panel content exactly-matched to gene panel in the AVENIO ctDNA Targeted Kit V2 (same genes, gene regions and hybrid-capture workflow) to facilitate analytical concordance between tissue and plasma
- All four mutation classes (SNVs, indels, fusions and CNVs) in a single DNA workflow
- Flexibility to switch between tissue and plasma to support a variety of research applications
- A streamlined, end-to-end research workflow from extraction to analysis and reporting in 5 days
- A complete research solution that includes reagents, intuitive analysis and reporting to facilitate in-house adoption of high performance NGS oncology testing
